



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Dr J Cheriyan
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST
HILLS ROAD,
CAMBRIDGE
CB2 0QQ
UNITED KINGDOM

08/06/2020

Dear Dr J Cheriyan,

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	CTA 12854/0251/001-0001
Eudract Number:	2020-002229-27
Product:	Forxiga 10mg (Dapagliflozin), Ambrisentan , EDP1815
Protocol number:	TACTIC-E

NOTICE OF ACCEPTANCE

I am writing to inform you that the Licensing Authority accepts your request for a clinical trial authorisation (CTA), received on 27/05/2020.

The authorisation is effective from the date of this letter although your trial may be suspended or terminated at any time by the Licensing Authority in accordance with regulation 31. You must notify the Licensing Authority within 90 days of the trial ending.

Finally, you are reminded that a favourable opinion from the Ethics Committee is also required before this trial can proceed.

Yours sincerely,

**Clinical Trials Unit
MHRA**